Zyflo CR (zileuton) Disease Interactions
There is 1 disease interaction with Zyflo CR (zileuton):
Zileuton (Includes Zyflo CR) ↔ Liver Disease
Severe Potential Hazard, High plausibility
Applies to: Liver Disease, Alcoholism
The use of zileuton is contraindicated in patients with active liver disease or transaminase elevations >= 3 times the upper limit of normal (ULN). Zileuton is primarily metabolized by the liver and may accumulate in patients with hepatic impairment. In addition, zileuton may cause elevation of serum transaminases, usually during the first two months of therapy but in a few cases, after treatment has been discontinued. During clinical trials, the overall rate of ALT (SGPT) elevation >= 3 times the ULN in patients treated with zileuton was 3.2%. The manufacturer recommends periodic monitoring of hepatic transaminases. Serum ALT should be evaluated prior to starting treatment, once a month for the first three months, every 2 to 3 months for the remainder of the first year, and periodically thereafter for patients receiving long-term zileuton therapy. If clinical signs and/or symptoms of liver dysfunction occur or transaminase levels increase to 5 times the ULN, treatment should be stopped, and transaminase levels followed until normal. Because of the potential hepatotoxicity, zileuton should be used with caution in patients with a history of liver disease or alcoholism.
- "Product Information. Zylo Filmtab (zileuton)." Abbott Pharmaceutical, Abbott Park, IL.
Zyflo CR (zileuton) drug Interactions
There are 136 drug interactions with Zyflo CR (zileuton)
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
|Major||Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderate||Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minor||Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.